Ongoing challenges for pharmacotherapy for dyslipidemia

Expert Opin Pharmacother. 2015 Feb;16(3):347-56. doi: 10.1517/14656566.2014.986094. Epub 2014 Dec 5.

Abstract

Introduction: While increasing evidence has led to lipid-modifying therapy achieving an important role in the treatment guidelines for the prevention of cardiovascular disease, these agents are suboptimally used and there remains a considerable risk of clinical events. Accordingly, there is a need to develop more effective lipid-modifying approaches in many patients.

Areas covered: A literature search was performed of topical manuscripts focusing on factors influencing use of established therapies and new agents in development that target a range of lipid factors.

Expert opinion: More intensive efforts are required to ensure that statin use is maximized in higher risk patients. A range of novel therapies, including proprotein convertase subtilisin kexin-type 9 and cholesteryl ester transfer protein inhibitors, may provide additional protection, although this remains to be established by clinical trials.

Keywords: atherosclerosis; cardiovascular risk; lipid-modifying therapy; lipids.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Cardiovascular Diseases / prevention & control
  • Cholesterol Ester Transfer Proteins / antagonists & inhibitors
  • Clinical Trials as Topic
  • Dyslipidemias / drug therapy*
  • Fatty Acids, Omega-3 / administration & dosage
  • Fibric Acids / therapeutic use
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Hypolipidemic Agents / therapeutic use*
  • Lipid Metabolism / drug effects
  • Niacin / therapeutic use
  • Proprotein Convertase 9
  • Proprotein Convertases / antagonists & inhibitors
  • Risk Factors
  • Serine Endopeptidases

Substances

  • Cholesterol Ester Transfer Proteins
  • Fatty Acids, Omega-3
  • Fibric Acids
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Hypolipidemic Agents
  • Niacin
  • PCSK9 protein, human
  • Proprotein Convertase 9
  • Proprotein Convertases
  • Serine Endopeptidases